Genome Engineering Global Market Report 2022: Increasing Funding and Investments for Research and Development Present Lucrative Opportunities
08 déc. 2022 06h08 HE
|
Research and Markets
Dublin, Dec. 08, 2022 (GLOBE NEWSWIRE) -- The "Genome Engineering Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Technology (CRISPR, TALEN, ZFN,...
U.S. Gene Editing Market Report 2022: Increasing Demand for Synthetic Genes Boosts Growth
16 nov. 2022 04h48 HE
|
Research and Markets
Dublin, Nov. 16, 2022 (GLOBE NEWSWIRE) -- The "U.S. Gene Editing Market - Industry Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.The U.S. gene editing...
CRISPR and CAS Genes Global Market to Expand by 26.82% Yearly Through 2029
07 nov. 2022 05h40 HE
|
Research and Markets
Dublin, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The "CRISPR and CAS Genes Market Analysis by Product & Service, by Application by End user, and by Region - Global Forecast to 2029" report has been...
Global CRISPR Technology Intellectual Property Landscape Report 2022: Identify Key Trends that Describe the Pace and Focus of Innovation Related to CRISPR / CAS Technologies
18 oct. 2022 08h53 HE
|
Research and Markets
Dublin, Oct. 18, 2022 (GLOBE NEWSWIRE) -- The "CRISPR Technologies: Intellectual Property Landscape(Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions, Patent...
Outlook on the Cell Therapy Global Market to 2028 - Increased Demand for Novel, Better Medicines for Diseases Such as Cancer and CVD Has Resulted in an Increase in General Research Efforts
05 oct. 2022 07h08 HE
|
Research and Markets
Dublin, Oct. 05, 2022 (GLOBE NEWSWIRE) -- The "Global Cell Therapy Market, By Use Type, By Therapy Type, By Product, By Technology & By Region- Forecast and Analysis 2022-2028" report has been...
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
16 sept. 2022 07h15 HE
|
Intellia Therapeutics, Inc.
Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses,...
Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
16 sept. 2022 07h00 HE
|
Intellia Therapeutics, Inc.
Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of...
Worldwide CRISPR Industry to 2028 - by Application, End-user and Region
15 sept. 2022 07h53 HE
|
Research and Markets
Dublin, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The "Global CRISPR Market 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global CRISPR market is anticipated to grow at a...
Global Genome Editing Market Report 2022: Continuous Technological Advancements in Gene-Editing Tools Driving Growth
29 août 2022 05h53 HE
|
Research and Markets
Dublin, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The "Genome Editing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology, Application, and End User" report has been added to...
Gene Therapy Market, 2035
09 août 2022 07h53 HE
|
Research and Markets
Dublin, Aug. 09, 2022 (GLOBE NEWSWIRE) -- The "Gene Therapy Market by Type of Therapy, Type of Gene Delivery Method Used, Type of Vector Used, Target Therapeutic Areas, Route of Administration, and...